Cladribine Tablets: A Potential New Short-course Annual Treatment for Relapsing Multiple Sclerosis

Jack C Sipe, MD


Expert Rev Neurother. 2010;10(3):365-375. 

In This Article


Therapy with cladribine tablets has the potential to become an important new treatment option for individuals with RRMS in terms of efficacy, safety/tolerability and ease of medication delivery. In the clinical trial setting, this preferential lymphocyte-reducing agent results in immunological modulation that reduces relapses, neurological disease activity and disease progression.[56] The short-course dosing regimen proposed in the CLARITY study is intended to provide patients with convenient future treatment options. An orally administered drug may result in improved compliance and adherence to treatment, maximizing the potential patient benefits. Therapy with cladribine tablets, which is currently in regulatory review, is potentially the latest addition to the first-line medications in the treatment of MS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: